ALX Oncology names Scott Garland chairman, hires Michael Listgarten as general counsel
The moves follow Corey Goodman's resignation as chairman for personal reasons, effective June 29, 2026.
ALX Oncology Holdings Inc. disclosed in an 8-K that Corey Goodman, Ph.D. informed the company on June 29, 2026 of his resignation as chairman of the board and as a board member, effective as of the close of business that day.1 The filing noted Dr. Goodman resigned for personal reasons and not due to any disagreement with the company over its operations, policies, or practices.1
In his place, the board appointed Scott Garland, who is an independent director of the company, to serve as chairman effective June 29, 2026.1 Garland had previously joined the ALX Oncology board, and according to the company, he has served on the board since November 2022, drawing on more than 30 years of biopharmaceutical industry experience, including commercial and operational expertise, to support the company's strategic and clinical priorities.1
The board also updated committee assignments. The audit committee is now chaired by Rekha Hemrajani, with Daniel J. Curran, M.D. and Scott Garland also serving as members.1 The compensation committee is chaired by Chris Takimoto, M.D., Ph.D., F.A.C.P., with Scott Garland also on that committee.1 The corporate governance and nominating committee is chaired by Daniel J. Curran, M.D., with Rekha Hemrajani as a member.1
Separately, the company named Michael Listgarten as general counsel. According to the release, Listgarten most recently served as general counsel at RAPT Therapeutics, where he led the legal and compliance function while supporting complex clinical development programs, regulatory strategy, and capital markets work.1 Earlier in his career, he served as Vice President of Healthcare Law and Chief Compliance Officer at Adamas Pharmaceuticals, and before that as Vice President of Healthcare Law at Principia Biopharma.1 He also spent 16 years at Genentech, Inc., where he led a large team of attorneys advising on legal and compliance matters supporting product development and commercialization.1
The company describes itself as a clinical-stage biotechnology company that is building a pipeline of experimental therapies aimed at treating cancer and extending patients' lives.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.